Introduction
============

The role played by platelets in determining cardiac ischemia/reperfusion (I/R) injury is not clear. Studies, conducted in the nineties, suggested that healthy platelets have cardioprotective properties. Indeed, healthy rat platelets resulted protective against myocardial injury induced by I/R in isolated rat hearts and by hypoxia/reoxygenation in cultured adult rat cardiomyocytes ([@B69], [@B67], [@B66], [@B70]; [@B68]; [@B35]). Subsequently, in a 2002 study, [@B36] infused pig platelets -- collected before or after coronary occlusion -- into Langendorff rat hearts, which were subsequently submitted to I/R. Only the pig platelets collected after reperfusion enhanced I/R injury in rat hearts. The authors concluded that the deleterious effect of platelets on reperfused myocardium depends on their activation status.

Recent studies by Cohen and Downey group have shown that P2Y~12~ receptor antagonists (e.g., Cangrelor, Ticagrelor) targeting platelets may exert a cardioprotective effect. Since the cardioprotective mechanism seems not attributable to inhibition of platelet aggregation ([@B71],[@B72]; [@B10], [@B11]), the authors suggest that patients treated with these antagonists are benefiting from protective "conditioning pathways" triggered by factors released by platelets. Indeed, these conditioning pathways are very similar to those activated by brief periods of intermittent non-lethal ischemia, before or after a prolonged ischemia, that are the well-known phenomena of pre- and post-conditioning ([@B11]; [@B41]; [@B45]). These conditioning phenomena induce the activation of protective pathways and a consequent reduction of I/R injury.

Many endogenous *molecules* could induce conditioning cardioprotection, eliciting specific pathways ([@B11]; [@B41]; [@B45]). Platelets are known to release a plethora of molecules, which mediate platelet effects in a variety of conditions, including cardioprotection against I/R injury ([@B69]; [@B43], [@B45]). A platelet-derived cardioprotective molecule is *Sphingosine 1-phosphate* (S1P), a bioactive lipid mediator abundantly carried and stored by platelets, whose production and release seem *redox-dependent* and related to thromboxane formation, but mechanisms are poorly understood ([@B73]; [@B55]; [@B56]; [@B39]; [@B52]).

S1P exerts its function through five specific cell surface receptors (S1PRs) on target organs ([@B55]; [@B63]) and is a double-edged sword: S1P is a potent proinflammatory and mediator of allergic diseases ([@B32]; [@B28]; [@B63]), but it is also a potent protectant against I/R injury ([@B61]). The S1P cardioprotection seems mediated by interaction with types 1--3 S1PRs, with subsequent activation of the so-called RISK/SAFE pathways ([@B61]; [@B12]). However, S1PR~1~ does not appear cardioprotective *in vivo*, whereas a combination of S1PR~2~ and S1PR~3~ activation mediates cardioprotection ([@B34]). Nevertheless, these studies revealed that S1P is an important mediator of cardioprotection and could induce either pre- or post-conditioning.

Several pathological conditions, including type 2 diabetes mellitus (T2DM), reduce the efficacy of ischemic conditioning strategies ([@B16]). However, unlike cardioprotection induced by ischemic conditioning, P2Y~12~ antagonist-induced conditioning can result in significant attenuation of I/R injury also in diabetic animals ([@B7]). These last results open an interesting scenario on the role of platelets in cardioprotection. Therefore, in-depth studies on platelet characteristics and their role in cardioprotection are necessary.

Of note, the S1P dynamic is profoundly altered in diabetic conditions ([@B17]) and diabetes is indicated as a "pro-thrombotic state" in which, among other alterations, *oxidative stress* and *platelet hyperactivity* play crucial roles in the cardiovascular complications ([@B21]). Therefore, one can wonder: are diabetic platelets cardioprotective and can reduce I/R damage? Although it is well known that diabetic platelets display a certain degree of activation ([@B64]; [@B21]), to the best of our knowledge, no studies ascertained whether the platelet-dependent cardioprotective properties are altered in the platelets of T2DM subjects.

Therefore, after a thorough study of platelet characteristics derived from healthy and T2DM subjects, we aimed to verify whether:

1.  *Human* healthy and diabetic platelets are cardioprotective in an isolated rat heart model;

2.  S1P and RISK-pathways play a role in platelet-induced cardioprotection;

3.  a correlation between platelet redox status (an index of platelet dysfunction) and myocardial I/R injury exists.

To these aims, blood samples were collected from voluntary healthy subjects and from T2DM patients. Platelet samples were analyzed for aggregatory aspects, ROS production and S1P release *in vitro* or were used to be infused in isolated hearts before being subjected to I/R protocols either in the absence or in the presence of S1P receptor blocker and RISK-pathway antagonists.

Materials and Methods {#s1}
=====================

Subjects and Platelet Preparation
---------------------------------

The study was performed on platelets obtained from 35 healthy volunteers and 16 type 2 diabetes mellitus (T2DM) patients. Healthy subjects were not on any antiplatelet therapy nor did they have any history of cardiovascular disease, metabolic syndrome or diabetes. Patients affected by T2DM were recruited among those attending the Metabolic Disease and Diabetes Unit of the San Luigi Gonzaga Hospital in Orbassano (Turin); six of them were at first diagnosis, the others were poorly controlled with glycated hemoglobin A1c (HbA1c) \> 7.5% even though on antidiabetic drugs. All subjects were without previous cardiovascular events and antiplatelet drugs in the previous 2 weeks. The totality of subjects gave informed consent before the investigation and the Ethics Committee of San Luigi Hospital approved the study, in accordance with the Declaration of Helsinki. The present study is a "case-control study" that raises potential issues of bias due to patient- and voluntary-donor selection. However, data collection was performed by blinded operators on the origin of platelets. Therefore, there is no subjectivity implied in the assessment or bias under these conditions.

Blood samples were collected from the antecubital vein and laboratory measurements were performed after a 12-h overnight fast. Biochemical parameters, including assessment of fasting glucose, total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and HbA1c as well as platelet number were measured using routine laboratory methods, performed by the central laboratory of our Hospital.

For studies concerning platelet function, a venous blood sample was withdrawn without stasis after an overnight fast, and anticoagulated with 3.8% sodium citrate, pH 7.4 (vol/vol: 1/9) for aggregation studies in platelet-rich plasma or with a citrate-dextrose solution (ACD; v/v, 1/6) for experiments on washed platelets. Platelet-rich plasma was obtained by using Platelet Function Centrifuge (BioData Corporation, Horsham, PA, United States) designed to provide a rapid separation of platelet-rich plasma by a centrifugation for 30 s and of platelet-poor plasma by a further centrifugation for 120 s. To prepare washed platelets, ACD-anticoagulated platelet-rich plasma, obtained by centrifugation at 100 × *g* for 20 min, underwent further centrifugation at 2000 × *g* for 10 min and pellet was washed two times at 37°C in HEPES-Na buffer (in mmol/L) (10 HEPES Na, 140 NaCl, 2.1 MgSO~4~, 10 [D]{.smallcaps}-glucose, pH 7.4).

Platelet Aggregation Studies
----------------------------

Platelet aggregation studies were carried out in both platelet-rich plasma and whole blood. Aggregation tests in platelet-rich plasma followed light-scattering changes as described by [@B8] using an eight-channel aggregation system (Platelet Aggregation Profiler, Model PAP-8, BioData Corporation) and were induced by ADP (10 μmol/L), arachidonic acid (AA, 1 mmol/L), and collagen (4 mg/L). Each aggregation test was recorded for 5 min and reported as percent of maximal aggregation.

For platelet aggregation in whole blood by impedance method, citrated blood samples were diluted 1:1 with physiologic saline and the tests were performed in a Chrono-Log Whole Blood Aggregometer, Model 500 at a constant stirring of 1000 rpm. Aggregation was induced with ADP (20 μmol/L), collagen (4 mg/L) or AA (1 mmol/L) and was recorded for 8 min. The maximum increase in resistance, expressed in ohms, was calculated.

### Reactive Oxygen Species (ROS) Assay

Intracellular ROS were evaluated in washed platelets by using the sensitive fluorescent indicator DCF-DA oxidized by H~2~O~2~ to the highly fluorescent DCF ([@B15]). Washed platelets (6 × 10^7^ ml^-1^) were exposed to 10 μmol/L cell permeant reagent DCF-DA and DCF fluorescence was measured at basal and after stimulation with AA (100 μmol/L) added just before measuring fluorescence. To examine specific signaling in basal ROS generation, platelets were preincubated for 20 min with the NADPH-oxidase inhibitors APO (10 μmol/L) or DPI (10 μmol/L), or the cyclooxygenase-1 (COX-1) inhibitor indomethacin (INDO, 100 μmol/l) ([@B18]; [@B3]).

Fluorescence was measured over a 60-min period at 1-min intervals using a plate fluorometer (GloMax-Multi Detection System, Promega Corporation, Madison, WI, United States) fitted with 490 nm excitation and 520 nm emission filters. Fluorescence per minute was calculated for each sample.

### Platelet S1P Assay

Washed platelets (500 μl for each sample containing 150 × 10^6^ platelets) were used to measure S1P release both in the absence (resting platelets) and in the presence of a stir bar put into the cuvette (stirring platelets) ([@B31]). For samples subjected to stirring, the stir bar inside the sample is spun, thus stirring the washed platelets to a 1200 rpm speed at 37°C. An eight-channel optical aggregometer was used (Platelet Aggregation Profiler, Model PAP-8, BioData Corporation) at this end. After 8-min incubation with or without collagen (4 mg/l), all samples were submitted to repeated freeze-thaw cycles to let out the inside components, centrifuged at 3000 rpm for 20 min and supernatants were collected for S1P measurement.

S1P levels were determined by using an Enzyme-Linked Immuno-adsorbent Assay according to manufacturer instructions (Bioassay Technology Laboratory, Shanghai, China). Standard curve range was 5--1500 ng/l, the sensitivity of the kit was 2.34 ng/l, and intra- and inter-assay CV were \<8% and \<10%, respectively.

### Western Blot Analysis in Platelets

To assess the activation state of platelets, we detected the phosphorylation/activation of phosphatidylinositol-3-kinases (PI3K) and extracellular signal-regulated kinases (ERK) in response to platelet agonists: washed platelets were stimulated by collagen (4 mg/L) or AA (100 μmol/L) for 8 min and the amounts of AKT, and pAKT, and ERK-2, pERK-1/2 were evaluated, respectively.

Cyclooxygenase-1 expression was also determined. Washed platelets samples were centrifuged and pellets solubilized in Laemmli buffer and processed as previously described ([@B51]). Membranes were incubated with rabbit anti-AKT, mouse anti-ERK-2 (Cell Signaling, Danvers, MA, United States), rabbit anti-phospho-Akt-Ser-473, mouse anti-phospho-ERK-1/2-Tyr-204, or mouse anti-COX-1 (Santa Cruz Biotechnology). As secondary antibodies, we used goat anti-mouse (Jackson Immuno Research Lab., West Grove, PA, United States) or goat anti-rabbit (Cell Signaling) antibodies conjugated to horseradish peroxidase. Blots were scanned and densitometrically analyzed by the image analyzer 1D Image Analysis software (Kodak, Rochester, NY, United States).

Animals
-------

Male Wistar rats (*n* = 75; 4--5-month-old, body weight 400--450 g, Harlan Laboratories Udine, Italy) were used for the *ex vivo* experiments as specified below. Animals were housed under controlled conditions with free access to standard rat diet and tap water. Rats received humane care in compliance with the European Directive 2010/63/EU on the protection of animals used for scientific purposes. The animal protocols followed in this study were approved by the local "Animal Use and Care Committee." In this study, six hearts were discarded due to the very low left ventricular developed pressure or other technical issues after connection to the perfusion line.

### Isolated Heart Preparations

Rats were anesthetized, heparinized (800 U/100 g b.w., i.m.), and hearts were rapidly excised, placed in an ice-cold buffer solution, and weighed. Isolated hearts were attached to the perfusion apparatus and retrogradely perfused with oxygenated Krebs--Henseleit buffer solution (KHS) containing (in mM): 127 NaCl, 5.1 KCl, 17.7 NaHCO~3~, 1.26 MgCl~4~, 1.5 CaCl~2~, 11 [D]{.smallcaps}-glucose (pH 7.4; 37°C; 95% O~2~/5% CO~2~). Hearts were kept in a temperature-controlled chamber (37°C), electrically paced at 280 b.p.m. The hearts were perfused in constant-flow mode and to assess the preparation conditions, coronary perfusion pressure and left ventricular pressure were monitored during all experiments ([@B43], [@B46]).

### Experimental Groups

To verify the cardioprotective properties of washed PLTs derived from healthy subjects (healthy-PLTs) or diabetic patients (diabetic-PLTs), hearts were assigned to one of the experimental groups described below on the basis of availability of the platelet donor. In all groups, the hearts were subject to 30 min stabilization, and 30 min of normothermic global ischemia followed by 60 min reperfusion (I/R). Protocols are as follow (**Figure [1](#F1){ref-type="fig"}**):

![Timeline of experimental protocols. Protocols of ischemia (black boxes) and reperfusion (white boxes) in isolated rat hearts. After stabilization (white boxes), Krebs-Henselite solution (KHS) was infused *via* a collateral line alone or with addition of washed PLTs and/or inhibitors (gray boxes). Washed platelets (PLTs) were given for 10 min before ischemia and inhibitors were given 5 min before PLTs and were stopped at the end of the 10 min of infusion of PLTs (total time infusion for inhibitors was 15 min). For further explanations, see the text.](fphys-09-00875-g001){#F1}

1.  In the I/R group (*n* = 7), after stabilization, only the I/R protocol was performed ([@B6]);

2.  In the healthy-PLT group (*n* = 8) healthy subject washed platelets diluted in KHS (healthy-PLTs, 3 × 10^7^ ml^-1^) were infused to the heart, via a collateral line, for 10 min at a flow rate of 12 ml/h; then hearts were subjected to I/R protocol;

3.  In the diabetic-PLT group (*n* = 8) diabetic patient washed platelets diluted in KHS (diabetic-PLTs, 3 × 10^7^ ml^-1^) were infused to the heart, via a collateral line, for 10 min at a flow rate of 12 ml/h; then hearts were subjected to I/R protocol.

For groups 2 and 3, each rat heart was treated with the platelets from a single donor and the platelet concentration and time of infusion were similar to those used by [@B69]. This relatively low concentration of platelets reduces the risk of capillary plugging and loss of myocardial function.

Since only healthy-PLTs affected significantly infarct size (see section "Results"), the following healthy-PLT+inhibitors groups were studied. In these groups, hearts were subjected to infusion of inhibitor alone for 5 min, then a co-infusion with healthy-PLT, for 10 min as in group 2, was performed, and, finally, the hearts underwent I/R protocol. Therefore, inhibitors were infused for a total of 15 min:

4.  In the healthy-PLT+VPC group (*n* = 5), to ascertain the involvement of S1P receptors in healthy-PLT-induced cardioprotective mechanisms, we used the S1P receptor blocker VPC23019 (1 × 10^-6^ M) as S1P1/3 receptor antagonist ([@B13]; [@B61]);

5.  In the healthy-PLT+U0126 group (*n* = 5), to ascertain the involvement of myocardial ERK1/2, we used the ERK1/2 antagonist, U0126 (60 × 10^-6^ M) ([@B37]);

6.  In the healthy-PLT+LY group (*n* = 5), to ascertain the involvement of myocardial PI3K/AKT, we used the PI3K antagonist, LY294002 (5 × 10^-5^ M) ([@B43]);

7.  in the healthy-PLT+CHE group (*n* = 5), to ascertain the involvement of myocardial PKC, we used the PKC antagonist, Chelerythrine (1 × 10^-6^ M) ([@B47]);

Inhibitors were also tested alone at the same concentrations and for the same periods:

8.  In the VPC23019 group (*n* = 5): hearts were subjected to infusion of VPC23019 for 15 min; then hearts were subjected to I/R protocol;

9.  In the U0126 group (*n* = 4): hearts were subjected to infusion of U0126 for 15 min; then were subjected to I/R protocol;

10. In the LY294002 group (*n* = 4): hearts were subjected to infusion of LY294002 for 15 min; then hearts were subjected to I/R protocol;

11. In the Chelerythrine group (*n* = 4): hearts were subjected to infusion of Chelerythrine for 15 min; then hearts were subjected to I/R protocol.

### Infarct Size Assessment

In order to assess infarct size extension, a gravimetric method was used in a blinded fashion. In briefly at the end of reperfusion, hearts were rapidly removed from perfusion apparatus and the left ventricular tissue was dissected into 2--3 mm circumferential slices. After 20 min of incubation at 37°C in 0.1% solution of nitro-blue tetrazolium in phosphate buffer, unstained necrotic tissue was carefully separated from stained viable tissue and weighed. The necrotic mass was expressed as a percentage of total left ventricular mass, which was considered as risk area ([@B44], [@B47]).

### Western Blot Analysis in Hearts

In additional experiments, immunoblot procedures and analyses were conducted as previously described ([@B46], [@B44], [@B47]). Immediately after the hearts had undergone I/R (*n* = 4) or PLT pretreatment (either healthy-PLTs, *n* = 8, or diabetic-PLTs *n* = 5), the cardiac specimens were frozen in liquid nitrogen before being stored at -80°C until protein extraction. Myocardial tissues of the above groups were homogenized in a frozen RIPA lysis buffer (Sigma-Aldrich, St. Louis, MO, United States) containing a mixture of protease inhibitors (1 mM of aprotinin, 20 mM of phenylmethylsulfonyl fluoride and 200 mM of sodium orthovanadate). Subsequently, myocardial homogenates were centrifuged at 15,000 × *g* for 25 min at 4°C for debris removal. Protein concentration was assessed using a Bradford reagent following the procedure described by the manufacturer (Sigma-Aldrich, St. Louis, MO, United States). Equivalent amounts of proteins (80 μg) were loaded and electrophoresed on SDS polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. Membranes were then incubated overnight at 4°C with primary antibodies mouse anti-phospho-ERK-1/2-Tyr-204 (Santa Cruz Biotechnology) or mouse anti-ERK-1/2 (Cell Signaling, Danvers, MA, United States). As secondary antibody, we used goat anti-mouse (Jackson Immuno Research Lab., West Grove, PA, United States). Blots were scanned and densitometrically analyzed by the image analyzer ID Image Analysis software (Kodak, Rochester, NY, United States).

Chemicals
---------

Collagen and arachidonic acid were purchased from Mascia Brunelli Spa (Monza, Milan, Italy). The sources of the specific antibodies are shown in the different sections. The other reagents were obtained from Sigma (St. Louis, MO, United States) if not differently specified.

Statistical Analysis
--------------------

Data are expressed as mean ± SE. Statistical analysis was performed with one-way analysis of variance (ANOVA) followed by Student's *t*-test or Newman--Keuls multiple-range test depending on the experiments. *P*-value ≤ 0.05 was considered to be significant. A linear fit is assessed between ROS production and infarct size. A *P*-value \< 0.05 was considered statistically significant.

Results
=======

The characteristics of study participants are shown in **Table [1](#T1){ref-type="table"}**. Healthy volunteers and T2DM subjects were significantly different for BMI (*p* \< 0.0001), HbA1c (*p* \< 0.0001), fasting glucose (*p* \< 0.0001), total cholesterol (*p* \< 0.0001), triglycerides (*p* \< 0.005), and LDL cholesterol (*p* \< 0.002). There were no differences between the two groups with regard to age, HDL-cholesterol, platelet number, systolic and diastolic blood pressure.

###### 

Clinical characteristics, laboratory findings, and medications of healthy and T2DM subjects.

                                     Healthy subjects (*n* = 35)   T2DM subjects (*n* = 16)   *p*-value
  ---------------------------------- ----------------------------- -------------------------- -----------
  M/F                                17/18                         7/9                        
  Age (years)                        53.0 ± 1                      57.1 ± 2                   0.08
  BMI (kg/m^2^)                      23.6 ± 0.2                    31.6 ± 2                   0.0001
  HbAlc (%)                          5.4 ± 0.1                     11.3 ± 0.8                 0.0001
  Fasting glucose (mg/dl)            84.9 ± 2                      320.5 ± 36                 0.0001
  Total cholesterol (mg/dl)          155.2 ± 4                     193.9 ± 13                 0.0001
  HDL cholesterol (mg/dl)            52.0 ± 1                      48.2 ± 2                   0.074
  Triglycerides (mg/dl)              105.0 ± 4                     151.9 ± 22                 0.005
  LDL cholesterol (mg/dl)            85.7 ± 4                      115.4 ± 10                 0.002
  SBP (mmHg)                         120.6 ± 1                     122.1 ± 8                  0.786
  DBP (mmHg)                         78.5 ± 0.8                    75.6 ± 2                   0.093
  Platelets (×l0^3^/μl)              236.2 ± 5                     243.9 ± 8                  0.401
  Insulin use                        --                            6 (38%)                    
  Oral antidiabetic medication use   --                            9 (56%)                    
  Statin use                         --                            10 (63%)                   
  Antihypertensive drugs use         --                            11 (69%)                   

HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Platelet Characteristics
------------------------

We first analyzed platelet (PLT) characteristics in both T2DM and healthy subjects.

### Platelet Aggregation Parameters Were Higher in Diabetic-PLTs Than in Healthy-PLTs

Platelet aggregation parameters were studied in diabetic-PLTs and in healthy-PLTs, in both platelet-rich plasma (**Figure [2A](#F2){ref-type="fig"}**) and whole blood (**Figure [2B](#F2){ref-type="fig"}**) samples. As shown in **Figure [2A](#F2){ref-type="fig"}**, in platelet-rich plasma, diabetic-PLTs, compared to healthy-PLTs, showed significantly higher aggregation to ADP (*p* \< 0.0001), collagen (*p* \< 0.0001), and AA (*p* \< 0.0001). In particular, in diabetic-PLTs, the aggregation was higher by about 35% in response to ADP, 47% to collagen, and 30% to AA.

![Effect of platelet exposure to different pro-aggregating agents: ADP, collagen (Coll) and arachidonic acid (AA). Platelet aggregation parameters were higher in platelets of diabetic patients (d-PLT) than in those of healthy subjects (h-PLT), in both platelet-rich plasma **(A)** or washed platelets **(B)**. ^∗∗^*p* \< 0.005, ^∗∗∗^*p* \< 0.0001 vs. h-PLT (unpaired *t*-test).](fphys-09-00875-g002){#F2}

As shown in **Figure [2B](#F2){ref-type="fig"}**, in whole blood, diabetic-PLTs, compared to healthy-PLTs, showed significantly higher aggregation to ADP (*p* \< 0.0001), to collagen (*p* \< 0.005), and AA (*p* \< 0.0001). Specifically, in diabetic-PLTs, the aggregation was higher by about 45% in response to ADP, 21% to collagen, and 53% to AA.

### S1P Release Was Lower in Diabetic-PLTs Than in Healthy-PLTs

The release of S1P was measured in supernatants of washed platelets in *resting* and *stirring* conditions (**Figure [3](#F3){ref-type="fig"}**). In *resting* platelet samples, S1P levels did not differ significantly between healthy- and diabetic-PLTs both in the absence (149 ± 6 vs. 112 ± 16 ng/l, *p* = ns) and in the presence of collagen (171 ± 3 vs. 132 ± 21 ng/l, *p* = ns).

![S1P release in washed platelets, in resting and stirring conditions. In resting conditions, S1P levels were not different between platelets from T2DM patients (d-PLT) and platelets from healthy subjects (h-PLT). +*p* \< 0.05 vs. resting basal. In stirring samples, S1P levels were lower in d-PLT than in h-PLT both in the absence and in the presence of collagen. ^∗^*p* \< 0.001, ^∗∗^*p* \< 0.0001 vs. healthy-PLT (unpaired *t*-test); ^\#^*p* \< 0.01, ^\#\#^*p* \< 0.005 vs. corresponding stirring basal; ^§^ *p* \< 0.005, ^§§^ *p* \< 0.001 vs. corresponding resting conditions (Newman--Keuls multiple-range test).](fphys-09-00875-g003){#F3}

When samples were subjected to *stirring*, a significant increase in S1P levels was observed in healthy-PLTs (from 149 ± 6 to 218 ± 10 ng/l, *p* \< 0.0001) but not in diabetic-PLTs (from 112 ± 16 to 148 ± 13 ng/l, *p* = ns). Furthermore, S1P levels, in stirring samples, were lower in diabetic-PLTs than in healthy-ones both in the absence (148 ± 13 vs. 218 ± 10 ng/l, *p* \< 0.001) and in the presence of collagen (199 ± 6 vs. 270 ± 7 ng/l, *p* \< 0.0001).

### ROS Levels Were Higher in Diabetic-PLTs Than in Healthy-PLTs

To ascertain whether higher aggregation parameters were associated with higher ROS levels, we used 2′,7′-dihydrodichlorofluoresceine diacetate (DCF-DA) oxidation to detect ROS intracellular concentration. As shown in **Figure [4A](#F4){ref-type="fig"}**, there was a significantly higher ROS level in resting, non-stimulated diabetic-PLTs than in controls (*p* \< 0.0001).

![Variation of the intra-platelet level of ROS measured by DCF fluorescence. **(A)** ROS level in resting platelets of diabetic patients (d-PLT) were higher than in resting platelets of healthy subjects (h-PLT). 20-min preincubation with apocynin (APO), diphenyleneiodonium (DPI), or indomethacin (INDO) reduced the levels of ROS produced by d-PLT. **(B)** PLT stimulation with arachidonic acid increased ROS levels in both h-PLTs and d-PLTs. ^∗∗∗^*p* \< 0.0001 vs. h-PLT; ^\#^*p* \< 0.005, ^\#\#^*p* \< 0.001 vs. resting d-PLT (paired *t*-test).](fphys-09-00875-g004){#F4}

To identify the origin of ROS, measurements were repeated after a 20-min pre-incubation with either apocynin (APO) or diphenyleneiodonium (DPI), two different NADPH-oxidase inhibitors, as well as the COX-1 inhibitor, Indomethacin (INDO). Data revealed that the basal ROS production in diabetic-PLTs is, at least in part, mediated by the activity of NADPH-oxidase and COX-1. In fact, with regard to baseline values, we observed a significant decrease of ROS production in the presence of NADPH-oxidase inhibitors, APO (*p* \< 0.001) or DPI (*p* \< 0.005), and COX-1 antagonist, INDO (*p* \< 0.001). As expected, platelet stimulation with AA increased ROS levels in both healthy-PLTs and diabetic-PLTs (**Figure [4B](#F4){ref-type="fig"}**). Furthermore, diabetic-PLTs generated a significantly higher ROS amount after stimulation with AA (6 vs. 9 fold increase, *p* \< 0.0001).

### COX-1 Expression and Signaling Transduction Molecules Were Up-Regulated in Diabetic-PLTs

We tested the hypothesis that the expression of constitutive COX-1 was higher in diabetic-PLTs. Indeed, as shown in **Figure [5A](#F5){ref-type="fig"}**, higher levels of COX-1 were present in diabetic-PLTs (*p* \< 0.0001).

![Protein content in platelets determined by Western blot. **(A)** Cyclooxygenase-1 (COX-1) levels were higher in platelets of diabetic patients (d-PLT) than in those of healthy subjects (h-PLT). **(B)** Phosphorylated Protein Kinase B (pAKT) and Phosphorylated Extracellular Signal-regulated Kinase-2 (pERK-2) were increased by collagen (Coll) and arachidonic acid (AA) stimulation in both h-PLT and d-PLT. However, the increases were higher in d-PLTs than in h-PLTs. ^\#\#\#^*p* \< 0.0001 vs. basal level; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.005, ^∗∗∗∗^*p* \< 0.0001 vs. h-PLT (unpaired *t*-test and Newman--Keuls multiple-range test).](fphys-09-00875-g005){#F5}

We argued that phospho-AKT (pAKT) and phospho-ERK-2 levels may be enhanced by the pro-aggregating agents more in diabetic-PLTs than in healthy-PLTs. As shown in **Figure [5B](#F5){ref-type="fig"}**, in healthy-PLTs and diabetic-PLTs, we found similar protein expression of AKT and ERK-2 (ERK-1 was not investigated) ([@B65]). To evaluate the agonist-induced activation of the PI-3K and ERK pathways, washed platelet samples were stimulated by either collagen or AA and pAKT and pERK level measured. As expected, the amount of pAKT increased in response to either collagen (*p* \< 0.0001 vs. baseline, for both groups) or AA (*p* \< 0.0001 vs. baseline for both groups). However, the increase was significantly greater in diabetic-PLTs than healthy-PLTs, for both collagen (*p* \< 0.01) and AA (*p* \< 0.0001). Similarly, the amount of pERK-2 increased in response to either collagen (*p* \< 0.0001 vs. baseline for both groups) or AA (*p* \< 0.0001 vs. baseline for both groups). Yet, the increase was greater in diabetic-PLTs than healthy-PLTs, for both collagen (*p* \< 0.05) and AA (*p* \< 0.005).

Isolated Hearts
---------------

Either healthy-PLTs or diabetic-PLTs were tested in isolated rat heart to verify their protective properties. Moreover, to ascertain the cardioprotective pathways activated by platelets, specific antagonists were used.

Of note, platelet infusion, as well as co-infusion with antagonists did not affect coronary perfusion pressure and left ventricular pressure (data not shown). These observations rule out impaired perfusion and plugged capillaries by platelets.

### Infarct Size Was Reduced by Healthy-PLTs Pretreatment Only, via S1P Receptors and ERK/PI3K/PKC Pathways

After I/R, in control group infarct size was 59 ± 3% of the left ventricular mass. The 10 min pre-treatment with healthy-PLTs significantly (*p* \< 0.005) reduced infarct size to 47 ± 2% of ventricular mass (**Figure [6A](#F6){ref-type="fig"}**). However, the 10 min pre-treatment with diabetic-PLTs did not reduce infarct size, which was 70 ± 2% of the left ventricular mass (Not Significant vs. I/R group; *p* \< 0.005 vs. healthy-PLT group).

![Infarct size expressed as percent of area at risk **(A,B)**, and platelet ROS-infarct size correlations **(C,D)**. **(A)** Washed platelets derived from healthy subjects (h-PLT) limited infarct size. The infarct size in hearts treated with platelets derived from diabetic patients (d-PLT) was higher than that observed in hearts pretreated with h-PLT. **(B)** The infarct size limitation effects of h-PLTs was abrogated by the blocker of S1P receptors, VPC23019, the antagonist of ERK1/2, U0126, the inhibitor of PI3K, LY or the antagonist of PKC, CHE. ^∗^*p* \< 0.005 vs. h-PLT; ^\#^*p* \< 0.005 vs. I/R; NS, not significant (Newman--Keuls multiple-range test). **(C)** Correlation between ROS platelet levels and infarct size for the d-PLT group (*n* = 7; linear regression). **(D)** correlation between ROS platelet levels and infarct size for the h-PLT group (*n* = 7; linear regression).](fphys-09-00875-g006){#F6}

To study the role of myocardial S1P receptors and RISK pathway, healthy-PLTs were alternatively co-infused with one of the following compounds: VPC23019 to block cardiac S1P Receptors (types 1 and 3), U0126 to inhibit ERK1/2, LY294002 to inhibit PI3K, or Chelerythrine to block PKC. At the end of reperfusion, in these four inhibitor groups, infarct sizes (66 ± 2%, 61 ± 2%, 61 ± 3%, and 63 ± 3% of the ventricular mass, respectively) were similar to those observed in control I/R hearts, but significantly (*p* \< 0.005 for all) higher than in healthy-PLTs group (**Figure [6B](#F6){ref-type="fig"}**).

The infusion of antagonists alone (VPC23019, U0126, LY294002, or Chelerythrine) did not affect infarct size, which was similar to control group (63 ± 2%, 59 ± 2%, 70 ± 5%, and 65 ± 3%, respectively, data not reported in the figure). These data are in agreement with previous studies ([@B43]; [@B61]; [@B37]).

### Diabetic Platelet ROS Levels Correlate With Infarct Size

We hypothesized a correlation between platelet ROS levels (an index of platelet dysfunction) and infarct size. Indeed **Figure [6C](#F6){ref-type="fig"}** displays a good correlation between platelet ROS levels and infarct size for data of diabetic-PLTs, whereas between ROS levels in healthy-PLTs and infarct size there is a poor, not significant, correlation (**Figure [6D](#F6){ref-type="fig"}**).

### Myocardial Phospho-ERK Is Involved in Healthy-PLT Induced Cardioprotection

To corroborate data obtained with inhibitors of survival kinases, we measured ERK-1/2 expression and phosphorylation in myocardial tissue of hearts treated with healthy-PLTs. The phosphorylation of ERK-1/2 was greater in hearts pre-treated with healthy-PLTs compared to hearts subjected to I/R (*p* \< 0.0001; **Figure [7](#F7){ref-type="fig"}**). A three--fourfold higher pERK/total ERK ratio was observed in healthy-PLT pretreated hearts compared to I/R hearts. In diabetic-PLT pretreated hearts the ratio was not different from that in I/R hearts.

![Phosphorylation of extracellular signal-regulated kinases (ERK-1/2) in lysates from hearts subjected to I/R only (control) or pre-treated with d-PLTs (washed platelets derived from diabetic patients) or h-PLTs (washed platelets derived from healthy subjects). Representative western blot of ERK-1/2 phosphorylation and total ERK-1/2 of protein extract from control I/R (*n* = 4), d-PLTs (*n* = 5), and h-PLTs (*n* = 8) hearts. Histograms represent the ratio of phosphorylated over total ERK protein expression. Data suggest that pretreatment with h-PLTs induces an increase in ERK-1/2 phosphorylation with respect to I/R only. ^∗^*P* \< 0.0001 vs. I/R; ^\#^*P*\< 0.001 vs. d-PLTs (Newman--Keuls multiple-range test).](fphys-09-00875-g007){#F7}

Discussion
==========

The main novel findings of this study are: (1) the heart pretreatment with platelets of healthy humans (healthy-PLTs) reduces infarct size, (2) the cardioprotective properties of healthy-PLTs depend on myocardial S1P receptor and RISK (PI3K-ERK-1/2-PKC) pathway activation, (3) the cardioprotective properties are lost by platelets from T2DM patients (diabetic-PLTs), which release less S1P than healthy-PLTs after mechanical and chemical stimulation, *in vitro*, and (4) the higher is the ROS level in PLTs the higher is infarct size in hearts pretreated with diabetic PLTs.

Pretreatment With Healthy Human PLTs Reduces Infarct Size via S1P Receptor Activation
-------------------------------------------------------------------------------------

Pre-treatment with healthy human PLTs limits infarct size in the Langendorff isolated rat heart. Thus, platelets may interact with uninjured organ to trigger protection in hearts subsequently subjected to I/R *ex vivo*. Data are in agreement with previous studies showing that perfusion of isolated rat hearts with platelets from normal rats protects against myocardial dysfunction caused by I/R, improving both biochemical and dynamic cardiac parameters ([@B69], [@B67]; [@B68]; [@B35]). Similar cardioprotection was observed in hearts perfused with platelet supernatant ([@B66], [@B70]), thus suggesting an important role for factors released by platelets.

In our model, the treatment of hearts with VPC23019, an S1PR~1~ and S1PR~3~ antagonist ([@B13]), abrogates cardioprotection induced by healthy-PLTs. Therefore, it is likely that healthy human platelets protect the hearts against I/R injury *via* an S1P mediated mechanism. Indeed, S1P is a platelet factor whose release originates from two pools: one constitutively secreted and located at the plasma membrane, and the other rapidly phosphorylated upon stimulation and mobilized from granules ([@B73]; [@B55]). This release in the supernatant is influenced by mechanical (stirring) and chemical (collagen) stimuli *in vitro*.

Intriguingly, S1P is a crucial signal molecule abundantly stored in platelets, which displayed a variety of cellular functions, including cardioprotective properties ([@B9]; [@B12]). S1P is stored within the platelets and is released in certain circumstances ([@B55]). Several studies performed in animal and *in vitro* models have proposed that S1P possesses cardioprotective effects ([@B29]; [@B20]; [@B76]; [@B23]; [@B32]). Moreover, S1P protects cultured rat neonatal cardiomyocytes from ischemia-induced cell death ([@B20]; [@B23]). Since only S1PR~1~, S1PR~2~, and S1PR~3~ are the receptor subtypes expressed in cardiac myocytes and endothelial cells ([@B48]; [@B22]; [@B33]; [@B75]), it is likely that these receptors play a major role in cardioprotection by healthy-PLT pretreatment. Indeed, in the heart binding of S1P to S1PR~1~ leads to activation of ERK1/2 and binding to the S1PR~3~ receptor promotes the activation of PI3K/AKT ([@B24]; [@B54]). Nevertheless, it is likely that the cardioprotective effect of S1P is the result of a co-operation of the three receptors expressed by the heart ([@B34]; [@B61]; [@B12]). That is why blocking both S1PR~1~ and S1PR~3~ with VPC23019, we blocked the platelet cardioprotective effects. It is unlikely that VPC23019 interfered with platelet S1P receptors because platelets express mainly S1PR~2~ and S1PR~4~ ([@B49]; [@B40]) (see also below "Methodological considerations *and limitations of the study*").

Infarct Size Limitation by Healthy-PLTs Is Reversed by RISK (PI3K, ERK-1/2, and PKC) Pathway Inhibition
-------------------------------------------------------------------------------------------------------

It has been reported that nitric oxide release may mediate cardioprotection by S1P ([@B14]). Since in the RISK pathway AKT is upstream to nitric oxide synthase, we verified whether inhibitors of RISK pathway may avoid platelet-induced cardioprotection. Indeed, healthy-PLT-induced cardioprotection was completely abolished by pre-treating the heart with LY294002 to block PI3K, or Chelerythrine to block PKC, as well as U0126 to inhibit ERK-1/2. Thus, suggesting a pivotal role of these survival kinases in the platelet-induced cardioprotection (**Figure [8](#F8){ref-type="fig"}**). A role which is corroborated by myocardial Western blot data, revealing elevated levels of *pERK-1/2* in healthy-PLT pretreated hearts only. This kinase phosphorylation is usually observed in conditioning treatments, with a peak of the pERK**/**total ERK ratio 10--15 min after the end of ischemia and a progressive reduction thereafter ([@B16]; [@B44]; [@B11]). A three--fourfold higher pERK/total ERK ratios in hearts pretreated with healthy-PLTs is a strong indication of kinase involvement in protection, especially if we consider that healthy-PLT pretreated hearts have just a 30% more vital tissue than control I/R hearts.

![Schematic representation of the intracellular pathway involved in the platelet/S1P cardioprotection.](fphys-09-00875-g008){#F8}

Moreover, since STAT3 seems to be downstream to ERK ([@B24]; [@B54]) in ongoing experiments we tested whether healthy or diabetic PLTs can activate myocardial STAT3. Indeed, we found that h-PLT treated hearts display a higher pSTAT3 level than d-PLT treated hearts (see **[Supplementary Materials](#SM1){ref-type="supplementary-material"}**).

However, it has been also shown that in some circumstances, platelets may contribute to initiation and propagation of I/R myocardial injury ([@B2]; [@B58]; [@B74]; [@B42]; [@B53]). These apparently conflicting reports may reflect different experimental designs: platelets introduced into the coronary system of heart preparations not before but during or after ischemia, atherosclerotic coronary arteries or coronary endothelial barrier failure. In particular, it has been suggested that the deleterious effects of platelets on reperfused myocardium depend on their activation status, which is enhanced by the previous exposure to I/R injured myocardium ([@B36]). In other words, it seems that in I/R scenario platelet deleterious effects are due to interaction with injured tissues and/or platelet pre-activation. Therefore, we studied the "*hyperreactive*" diabetic-PLTs.

Cardioprotective Properties Are Lost by Diabetic-PLTs
-----------------------------------------------------

The cardioprotective properties seen for healthy-PLTs are lost by diabetic-PLTs. In fact, infarct size after intracoronary pretreatment with diabetic-PLTs is significantly higher than that observed in hearts pre-treated with healthy-PLTs and not significantly different from the control I/R hearts. This is in agreement with the idea that activated platelets lose the cardioprotective properties ([@B36]).

Multiple factors may cause dysregulation of platelet signaling pathways leading to a hyper-reactive platelet phenotype. Indeed, diabetic subjects of our study were not only characterized by hyperglycemia and uncontrolled diabetes but also by other dysmetabolic conditions such as obesity and dyslipidemia, commonly associated with T2DM, and each of them may contribute to the diabetic-PLT hyper-reactivity observed in this population ([@B50]; [@B38]). In this study, we confirm that, in comparison with healthy-PLTs, platelets from T2DM patients show: (a) higher aggregating response to agonists (b) higher basal and AA-induced production of ROS, (c) enhanced levels of COX-1 and (d) increased levels of *phospho-AKT* and *phospho-ERK-2* upon stimulation with agonists, more in diabetic than healthy platelets, thus confirming the hyper-reactivity of diabetic platelets. However, unlike myocardium, these two kinases are not linked to a survival signaling in platelets ([@B26]; [@B1]). Indeed, *following stimuli*, ERK and AKT regulate platelet activation and function, such as adhesion or secretory changes, and are actively involved in conveying signals from several pathways leading to platelet activation ([@B26]; [@B1]).

Our findings on platelet function in T2DM subjects fit into the general picture of the current research that describes platelet hyper-reactivity as responsible, at least in part, of the prothrombotic state in T2DM ([@B21]). We also demonstrate that higher ROS levels in diabetic-PLTs are, at least in part, due to enhanced production by NADPH-oxidase and COX-1 activity. Indeed, ROS generation in diabetic-PLTs is mostly produced by COX-1 activity, as shown by the significant reduction of ROS levels using the COX-1 inhibitor, INDO. A role is also played by the pro-oxidant enzyme NADPH-oxidase, as shown by the significant reduction of ROS levels when diabetic-PLTs were preincubated with two different NADPH-oxidase inhibitors, APO or DPI. Several reports have suggested that ROS represent a new modulator of platelet activity and ROS generated by platelets have a direct role in the control of their responsiveness ([@B59]).

The correlation between platelet ROS levels in diabetic platelets and the extension of infarct size suggests that the redox status in these platelets may play a pivotal role in influencing their cardiac effects. The absence of correlation for healthy platelets suggests that a certain threshold of ROS should be reached to affect protective properties. Of note, a complete prevention of the post-ischemic cardio-depressive effects by platelets -- administrated during ischemia or reperfusion on isolated guinea pig hearts -- was observed after platelet pretreatment with the NADPH-oxidase inhibitor, DPI ([@B53]). These data are in agreement with our data that ROS levels in hyperactive platelets are correlated to the extension of I/R injury and that platelet ROS derive, at least in part, from NADPH-oxidase. Nevertheless, correlation is not causality and our results need further studies to clarify the role of ROS.

Here, we show that diabetic platelets release less S1P when mechanically (*stirring*) or chemically (collagen) stimulated. Our findings are in line with the observation that diabetic platelets have a dysregulation of the S1P component ready to be mobilized ([@B27]). Moreover, the fact that S1P release is compromised is in agreement with the observation that diabetic platelets display higher expression of signs and factors of dysregulation, including higher ROS amount produced at basal condition and after stimulation with AA. In other words, the loss of protective properties observed in diabetic platelets could be linked to the altered redox and aggregatory conditions of these platelets that would alter the modality and/or quantity of released S1P. However, this hypothesis needs more experiments to be fully ascertained. Also, the consequences and mechanisms of S1P dysregulation in diabetic platelets need to be further investigated.

Methodological Considerations and Limitations of the Study
----------------------------------------------------------

The main aim of the present study was to ascertain the mechanisms of platelet-induced cardioprotection. However, diabetic PLTs were not protective and it remains to ascertain the reasons for this ineffectiveness. Indeed, the use of a normal heart allowed us to rule out that the lack of protection is due to myocardial resistance to protection, typical of diabetes and other co-morbidities ([@B16]). The defect is likely within diabetic platelets: the impaired release of S1P may prevent protection from diabetic-PLTs. However, it cannot be so easily determined because these platelets are ineffective in influencing the infarct size in Langendorff hearts: blocking myocardial S1P receptors or RISK pathway will not reveal the mechanism of diabetic-PLTs ineffectiveness. It may be also argued that blocking ROS production with antioxidants in washed platelets may reverse the platelet defect but ROS blockers/scavengers may interfere directly with myocardial I/R injury and/or platelet S1P release. Therefore, future studies should envision appropriate protocols to solve these open questions and, in particular, the reasons for diabetic-PLTs ineffectiveness.

Although the Langendorff's model, like all experimental paradigms, has disadvantages and advantages, it is a useful paradigm for studying the role of cardioprotective procedures ([@B6]). Indeed, Langendorff's model allows to subjecting the heart to a "clean" test, and to remove unwanted interferences by blood cells, protein and other "confounding variables," such as temperature, perfusion, and neuro-hormonal influences. Indeed, experiments performed on Langendorff's murine model provided very strong data on the cardioprotective effect of S1P ([@B20]; [@B30]; [@B60], [@B62]).

It is unlikely that the S1PR~1/3~ antagonist, VPC23019, interfered with the capacity of platelets to release S1P. It has been reported that human platelets may express types 1, 2, and 4 of S1PRs ([@B19]; [@B57]). However, Fleming and co-workers were able to detect S1PR~2~, but not S1PR~1~ on human platelets ([@B49]); in this study, S1PR~2~ displayed a pro-aggregating role. In another study, it has been suggested that S1P suppresses collagen-induced aggregation *via* S1PR~4~, but not through S1PR~1~ in human platelets ([@B40]). Therefore, it seems that human platelets express S1PR~2~ and S1PR~4~, with a pro- and anti-aggregant role, respectively. Whether S1PR~1~ is present and/or play a role seems controversial. Therefore, VPC23019 may not interfere with the principal receptors present on platelets, but it is specific for the receptors expressed by the cardiac tissues. Nevertheless, S1PRs are involved in platelet-induced cardioprotection.

We used a commercially available ELISA kit for the assessment of S1P release in washed platelets. This differs from protocol usually performed to measure S1P levels in serum or plasma samples where high-density lipoproteins are the major plasma carriers for S1P. Clearly, S1P values in our study are not comparable to those obtained in blood/plasma samples.

We used washed platelets, therefore it is unlikely that the S1P was already in the perfusate. Only the S1P released by circulating platelets may be involved in the cardioprotective effect. Indeed, stirring may simulate the circulating conditions that allow the release of larger quantities of S1P. Nevertheless, in future studies, it might be worthwhile to test whether platelet-derived supernatant can be protective *via* S1P mechanism.

*In summary*, three key observations regarding the platelet function and role in I/R scenario were made in this study: (1) S1P/S1PRs play important roles in determining healthy-platelet-induced cardioprotection *via* myocardial RISK pathway, in an isolated rat heart model, (2) these cardioprotective properties are lost by diabetic platelets, which produce higher levels of ROS and lower levels of S1P when stimulated *in vitro*, and (3) infarct size correlates with the amount of ROS produced by diabetic platelets.

Conclusion
==========

Here we provide evidence that human healthy platelets exert cardioprotective effects *via* activation of an S1P related mechanism. It is likely that myocardial RISK pathway plays a pivotal role in platelet-induced cardioprotection. Our data also suggest that alterations in ROS production and in S1P release may be involved in the impairment of function and the loss of cardioprotective properties by diabetic platelets. Since plasma S1P concentration is reduced in patients with myocardial infarction ([@B25]), its modulation by drugs targeting platelets might be very important and need to be better understood. Since exosomes greatly contribute to platelet activity, whether and how the platelet-induced cardioprotection is linked to the well-known exosome-induced cardioprotection ([@B5], [@B4]) remain to be elucidated. Further studies in this direction are warranted.
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